Abstract
Nivolumab is still relatively new modality of treatment that we use nowadays to treat many malignant diseases such as renal carcinoma, urotelial carcinoma, lung carcinoma as well as malignant melanoma. Despite its excellent treatment results it comes with a number of side effects such as skin rash, colitis, pneumonitis or hepatitis.
Most of its side effects are well manageable and do not require permanent cessation of treatment. In this described case report we see relatively rare case of severe hepatopathy which did not respond to conventional immunosuppressive therapy and led to permanent cessation of nivolumab treatment.
Diagnostic procedures, therapeutic judgment, and each line of immunosuppressive treatment as well as managing their side effects are discussed here. In the discussion the whole case report is commented and compared with data available in literature.